Adaptive Announces Launch Of Epic Integration For clonoSEQ
Portfolio Pulse from Benzinga Newsdesk
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has announced the integration of its clonoSEQ test into Aura, Epic's specialty diagnostics suite. This will allow healthcare providers to order and review clonoSEQ minimal residual disease (MRD) testing results directly in Epic.
September 13, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The integration of Adaptive Biotechnologies' clonoSEQ test into Epic's Aura could potentially increase the usage and visibility of the test, potentially leading to increased revenues for the company.
The integration of clonoSEQ into Epic's Aura will make the test more accessible to healthcare providers, potentially leading to increased usage. This could result in increased revenues for Adaptive Biotechnologies.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100